Baxter Ventures has led a $10m series B round for Prescient Surgical, which also attracted corporate-backed Summation Health Ventures.

AstraZeneca, Merck and Alexion-backed Moderna Therapeutics has set its pricing range at $22 to $24 and would raise more than $521m if it floats at the top end.

The company will take its wearable technology and healthcare platform to Japan following a Mitsui-led series B round that was worth between $30m and $35m.

UCL spinout Engitix plans to develop therapeutics for liver fibrosis and certain cancers based on its targeted drug discovery platform.

Ireland Strategic Investment Fund has led a $200m series C round for Wuxi NextCode after the latter’s acquisition of ISIF and GV-backed Genomics Medicine Ireland.

University of Lisbon-founded biotherapeutics developer is targeting infectious, metabolic and intestinal conditions, and has collected $2.8m from a fund run by Seventure Partners.

IP Group is among the investors in x-ray technology developer Ibex Innovations’ latest round after backing a $3m round for the company in 2014.

Cambridge Enterprise-backed Fluidic Analytics' third funding round will help fund the launch of its first microfluidics-based protein analysis machine.

Merck & Co and AbbVie co-led the biotech company's funding round, which included Mayo Clinic, Alexandria Venture Investments and Amgen.

Roel Bulthuis, senior vice-president and managing director at M Ventures, has moved on to Inkef Capital as head of healthcare and is succeeded by Jasper Bos at the corporate venture capital unit.